Last updated on February 2011

Triptorelin Flutamide and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Prostate Cancer
  • Age: - 74 Years
  • Gender: Male
  • Other:
    DISEASE CHARACTERISTICS:
    Histologically confirmed prostate cancer, meeting the following clinical staging
    criteria:
    Stage T1b-T1c AND prostate specific antigen (PSA) ≥ 10 ng/mL OR Stage T1b-T1c
    AND Gleason score ≥ 7 OR Stage T2a-T3a
    No lymph node invasion (N0 or N-)
    Patients with ≥ 10% risk by the Partin table must undergo curage
    No metastatic disease (M0) by thoracic radiography and bone scan
    PSA < 30 ng/mL
    No history of invasive cancer
    PATIENT CHARACTERISTICS:
    Age
    Under 75
    Performance status
    ECOG 0-1
    Life expectancy
    At least 10 years
    Hematopoietic
    Not specified
    Hepatic
    Not specified
    Renal
    Not specified
    PRIOR CONCURRENT THERAPY:
    Biologic therapy
    Not specified
    Chemotherapy
    Not specified
    Endocrine therapy
    No prior hormonal therapy
    Radiotherapy
    No prior pelvic radiotherapy
    Surgery
    No prior radical prostatectomy
    No prior castration

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.